Netakimab

尼塔奇单抗

Report date: 2025/11/03 16:01:24
First In Class

Base Information

Drug NameNetakimab
Drug Alias NameEfleiraBCD-085
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-17 inhibitors
TargetsInterleukin-17
Therapy Area/IndicationsPlaque psoriasisPsoriasisLiver Cirrhosis, Biliary +[5] 
Global Approved IndicationsPsoriasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2019/05/01
Country/TerritoryRussian FederationBelarusMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesSPH-BIOCAD Biopharmaceuticals (SH) Co LtdBIOCAD JSCSPH-Biocad (HK) Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing +[4] 
Inactive IndicationsLiver Cirrhosis, Biliary

Other Information

ATC CodeL01XC
Related LinksN/A